Introduction
Lynch syndrome (LS) (MIM# 120435) is the most common form of inherited colorectal and endometrial cancer, predisposing also to other gastrointestinal (GI) (stomach, small bowel, biliary tract, pancreas) and non-GI cancers (urinary tract, ovary, and others). The syndrome is transmitted as an autosomal-dominant trait, and caused by constitutional defects in the mismatch repair (MMR) genes MLH1 (MIM# 120436), MSH2 (MIM# 609309), MSH6 (MIM# 600678), and PMS2 (MIM# 600259) [Lucci-Cordisco et al., 2003; Lynch and De la Chapelle, 2003 ]. Detection of a constitutional loss-of-function variant in an MMR gene provides diagnostic confirmation of LS and is essential for the identification of at-risk members in LS families through predictive testing. This is especially important for LS care, since carriers of MMR gene pathogenic variants can benefit from different risk-reducing options, including stringent surveillance protocols, prophylactic surgery, and chemoprevention [Vasen et al., 2013] .
A major challenge in the diagnosis and management of LS is the frequent occurrence of variants of uncertain significance (VUS) in the MMR genes. Depending on the gene, about one-fifth to onethird of DNA sequence variants identified during the course of LS clinical testing are of uncertain significance [Sijmons et al., 2013] , limiting risk reduction and management options in probands and preventing their use in predictive gene testing in relatives.
The classification of DNA sequence variants identified in MMR and other cancer predisposition genes is recommended to be based on data from multiple sources, including clinical observations, tumor pathology studies, and several RNA-and protein-based functional assays Hofstra et al., 2008; Spurdle et al., 2008; Tavtigian et al., 2008a; Richards et al., 2015] . A number of in silico programs have also been devised to assist with the prediction of functional consequences of inherited MMR gene alterations [Tavtigian et al., 2008b; Thompson et al., 2013b; Niroula and Vihinen, 2015] .
Recently, the International Society for Gastrointestinal Hereditary Tumors (InSiGHT) has developed criteria for the interpretation of MMR gene variants, with the aim to improve the clinical utility of genetic testing for LS. A systematic clinical classification of all variants contained in InSiGHT locus-specific databases (http://insight-group.org/variants/database/) was performed, based on a multifactorial bayesian quantitative approach and/or on stringent combinations of qualitative clinical and functional data [Thompson et al., 2014] . Variants were classified using a five-tier system devised for cancer predisposing genes [Plon et al., 2008] .
In the present study, we assessed the pathogenicity of 24 MMR gene variants using an extensive combination of RNA-and proteinbased functional assays, segregation studies, and tumor analyses. We were able to classify six novel variants as well as to confirm or refine the classification of 18 variants previously assessed by InSiGHT. Overall, we show the necessity of using different analyses in VUS classification and discuss their specific value and status in the interpretation process.
Materials and Methods

Genetic Variants, Patients, and Samples
The variants assessed in this study were detected in a single laboratory in families fulfilling the Bethesda criteria [Vasen, 2005] ascertained through cancer family clinics from 2002 to 2011. Overall, 57 MMR gene variants (25 MLH1 and 32 MSH2) , excluding well-established polymorphisms, were detected in a total of 56 families. Variants that were clearly disease-causing (i.e., truncating, splicing alterations, or large rearrangements), as well as established polymorphisms, were not considered. Exceptions were some alleles that, despite being currently considered polymorphic, were not clearly classified at the time of their detection; these included MLH1 c.1558+14G>A, and MSH2 c.380A>G and c.1511-9A>T, whose assessment was useful for the validation of the variables investigated for classification. Overall, we evaluated 24 MMR gene variants, 13 MLH1 and 11 MSH2, identified in 37 unrelated families. All variants were single-nucleotide substitutions at the genomic level. Based on their positions in the DNA sequence and predicted effects, they could be divided into the following groups: 12 aminoacid substitutions (eight in MLH1 and four in MSH2), one MLH1 potential splice-site change affecting the first exonic position and also potentially causing an aminoacid substitution, four synonymous exonic nucleotide substitutions (one MLH1 and three MSH2), and seven intronic changes outside the most conserved positions of the splicesite consensus sequences (four MLH1 and three MSH2). Six variants (four MLH1 and two MSH2) were previously unreported and therefore not assessed by InSiGHT.
Peripheral blood leukocyte (PBL) samples were collected from 76 and 16 subjects for DNA and RNA extractions, respectively. Furthermore, lymphoblastoid cell lines (LCLs) were established from seven variant carriers. Forty-nine paraffin-embedded tumor specimens were obtained from 42 carriers of 23 different variants.
The study was approved by the Institutional Ethical Board of the Careggi University Hospital, Florence. Informed consent was obtained from all patients for the use of specimens and clinical/pathological data for research purposes.
Molecular Analyses
The complete coding sequence and flanking exon-intron borders of the MLH1 and MSH2 genes were investigated by direct sequencing on genomic DNA. The presence of MLH1 and MSH2, as well as of EPCAM (MIM# 185535), genomic rearrangements, and the methylation status of the MLH1 promoter were investigated by multiplex ligation-dependent probe amplification, as previously described [Crucianelli et al., 2014] . Values lower than 0.15 were assumed as a cut-off for normal methylation levels according to previous studies [Gylling et al., 2007; Crucianelli et al., 2014] .
The identified MLH1 and MSH2 variants have been submitted to the InSiGHT MMR gene variant database (http://www.insight-group.org/variants/database/). Variants were defined according to the Human Genome Variation Society (HGVS) recommendations [den Dunnen et al., 2016] . DNA variant numbering is based on the MLH1 and MSH2 cDNA sequences (GenBank accession numbers NM 000249.2 and NM 000251.1, respectively) with the A of the ATG translation-initiation codon numbered as +1. Aminoacid numbering starts with the translation initiator methionine as +1.
To investigate the presence of the p.Val600Glu (V600E) hotspot mutation, BRAF (MIM# 164757) exon 15 was directly sequenced in seven tumor samples of MLH1 variant carriers, using previously reported primers and conditions [Mancini et al., 2010] .
Loss of heterozygosity (LOH) analysis of the regions containing the identified variants was performed on matched leukocyte and tumor tissues from 19 probands by analysis of direct sequencing electropherograms [Janssen et al., 2011; Janssen et al., 2012] .
Microsatellite Instability and Immunohistochemical Analyses
A total of 47 tumor samples and matched normal mucosa or PBLs from 40 patients were evaluated for microsatellite instability (MSI) using a 5-mononucleotide marker panel [Suraweera et al., 2002; Buhard et al., 2006; Giunti et al., 2009] . Tumors were classified into three categories according to the proportions of markers showing instability: MSI-H (high-level MSI), MSI-L (low-level MSI), and MSS (microsatellite stable), which have ࣙ30%-40%, >0%-<30%-40%, and 0% unstable markers, respectively [Boland et al., 1998 ]. Immunohistochemical (IHC) analysis of MMR protein expression was performed on paraffin-embedded tumor tissue sections from 42 samples, as previously described [Roncari et al., 2007] .
Allelic Frequencies in Control Chromosomes
To assess frequencies of the 24 MLH1 and MSH2 variants in control chromosomes, one-hundred and sixty DNA samples from anonymized healthy Italian blood donors with no history of colorectal cancer among first-degree relatives and from the same region of origin (Tuscany) of most of the patients were analyzed by HUMAN MUTATION, Vol. 38, No. 1, 64-77, 2017 direct sequencing. In addition, the Exome Aggregation Consortium database (ExAC Browser [Beta] , http://exac.broadinstitute.org/, 04/2016 accessed) was interrogated, excluding the Cancer Genome Atlas (TGCA) data.
Cosegregation with Phenotype and Multifactorial Likelihood Analysis
Cosegregation analysis was performed for 11 variants in 16 families; in these, 24 affected carrier relatives, in addition to probands, were identified. The variants were detected by direct sequencing. Multifactorial likelihood analysis was performed for 14 variants for which sufficient data were available, as described previously [Thompson et al., 2013a [Thompson et al., , 2013b . Briefly, a probability of pathogenicity (Thompson et al., 2003) based on variant location or in silico scoring of missense substitutions is combined with likelihood ratios for segregation and tumor characteristics (MSI/BRAF status) to derive a posterior probability of pathogenicity.
mRNA Splicing Analysis
Total RNA was extracted from the seven cycloheximide-treated and untreated LCLs established from MLH1 or MSH2 variant carriers, using RNeasy R Plus Mini Kit (Qiagen, Hilden, Germany). Cycloheximide (Sigma-Aldrich, Saint Louis, MO) was added at 10 μg/ml to the medium 4 hr before harvesting the cells to prevent degradation of unstable transcripts by nonsense-mediated decay (NMD). cDNA was synthesized using TaqMan Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Primers and conditions used for cDNA amplification are available upon request. PCR products were analyzed on agarose gels, and individual bands, corresponding either to the full length or to the aberrantly spliced transcripts were excised and eluted using the QIAquick Gel Extraction Kit (Qiagen) before amplification and direct sequencing. All RT-PCR experiments were performed in duplicate. Since alternative splicing is commonly observed for MLH1 and MSH2 [Genuardi et al., 1998 ], to improve the detection and interpretation of splicing aberrations, eight control samples were also analyzed [Thompson et al., 2015] .
Allele-Specific Expression Analysis
Allele-specific expression (ASE) was investigated by singlenucleotide primer extension (SNuPE) in 10 patients heterozygotes for the coding SNPs rs1799977 (MLH1 c.655G>A) or rs4987188 (MSH2 c.965G>A), as previously described [Crucianelli et al., 2014] . Total RNA was extracted from blood samples collected into PAXgene Blood RNA tubes (PreAnalytiX; Qiagen), using the PAXgene Blood RNA Kit (Qiagen) according to the manufacturer's instructions. Samples from heterozygotes for the same SNPs who had no additional MLH1 and MSH2 sequence change were used as controls [Perera et al., 2010; Pastrello et al., 2011] . ASE was calculated after measuring peak heights in heterozygous samples [Castellsagué et al., 2010] . Values included in the 0.8-1.2 range were assumed as a cut-off for normal ASE according to previous studies [Renkonen et al., 2003; Castellsagué et al., 2010; Perera et al., 2010] . All experiments were carried out in triplicate and two independent replicates of all experiments were performed. Control heterozygotes for the MLH1 or MSH2 exonic polymorphisms (rs1799977 and rs4987188, respectively) were included in each experiment.
Minigene Splicing Assay
Splicing assays were performed by comparing the splicing pattern of wild-type (WT) and mutant minigenes transiently expressed in HeLa cells [Soukarieh et al., 2016] . Two different vectors were used in the minigene splicing assay: pCAS2 or pSPL3m [Soukarieh et al., 2016] , as specified. Except for two constructs (MSH2 c.2006-6T>C and c.2081T>C) , minigenes were prepared by first PCR-amplifying WT and mutant genomic segments from patients' DNA using forward and reverse primers mapping approximately at 150 nucleotides upstream and downstream the exon of interest, respectively. Primer sequences are available upon request. The PCR products were then inserted into the intron of pCAS2 to generate splicing reporter minigenes as previously described [Tournier et al., 2008] . Minigenes carrying the single variants MSH2 c. 2006-6T>C and MSH2 c.2081T>C (present in cis in patient genomic DNA) were prepared by sitedirected mutagenesis by using a two-stage overlap extension PCR method [Ho et al., 1989] . The psPL3m construct carrying MLH1 c.301G>A was generated by transferring the insert from the previously described minigene pCAS1.MLH1.exon3.c.301G>A [Tournier et al., 2008] .
Protein Stability and In Vitro MMR Activity Analyses
Altogether, nine MLH1 and MSH2 missense variations were introduced into the MLH1 and MSH2 cDNAs cloned into a pFastBac1 vector (Invitrogen, Carlsbad, CA), using a PCR-based sitedirected mutagenesis kit according to manufacturer´s instructions (QuikChange Lightning R Site-Directed Mutagenesis Kit; Stratagene, La Jolla, CA). The mutated constructs were sequenced (ABIPrism 3100 Genetic Analyzer; Applied Biosystems) prior to protein production. Primer sequences and PCR parameters are available upon request.
Recombinant baculoviruses were generated by Bac-to-Bac system (Invitrogen) and proteins were produced in Spodoptera frugiperda (Sf9) insect cells as described earlier [Kariola et al., 2002; Nyström-Lahti et al., 2002; Ollila et al., 2006] . For protein production, Sf9 cells were coinfected with MLH1 and PMS2 viruses to yield MutLα heterodimers, or MSH2 and MSH6 viruses to yield MutSα heterodimers. The total protein extracts (TE) were prepared as previously described [Kariola et al., 2002; Nyström-Lahti et al., 2002] .
The expression levels of produced protein variants were studied by Western blot analysis. The proteins were blotted onto nitrocellulose membranes (Hybond, PVDF; Amersham Pharmacia Biotech, Uppsala, Sweden) and visualized with anti-MLH1 (BD Biosciences/Pharmingen, San Diego, CA; clone 168-15) (0.5 μg/ml), anti-PMS2 (Calbiochem/Oncogene Research, San Diego, CA; Ab-1) (0.2 μg/ml), anti-MSH2 (Calbiochem; MSH2-Ab1, NA-26) (0.2 μg/ml) and anti-MSH6 (BD Transduction Laboratories, Lexington, KY; clone 44) (0.02 μg/ml) monoclonal antibodies. To estimate the MMR protein level in the extracts, α-tubulin was used as a loading control (anti-α-tubulin; Sigma-Aldrich; DM1A) (0.2 μg/ml).
The repair efficiencies (R%) of the recombinant protein variants were analyzed by complementing the MMR-deficient nuclear extracts (NEs) of HCT116 or LoVo cells (American Type Culture Collection, Manassas, VA) with the Sf9 TEs containing overexpressed MLH1 or MSH2 proteins Kantelinen et al., 2012] according to the protocol previously described [Kantelinen et al., 2012] . Seventy-five μg of NE was incubated with TE including in each sample comparable amounts of MutLα or MutSα, respectively, and with an excess amount (100 ng) of the heteroduplex DNA substrate. R% was calculated as an average of three independent experiments using GeneTools 3.08 (SynGene, Cambridge, England). The relative R% was calculated in respect to the WT control [Drost et al., 2010; Kantelinen et al., 2012] .
Clinical Classification of Variants
The five class system for clinical classification recommended by the International Agency for Research on Cancer (IARC) working group on the interpretation of DNA sequence variants in cancer predisposition genes was used [Plon et al., 2008] . Class 5 and 4 include definitely pathogenic and likely pathogenic variants, respectively; when observed in a proband, they provide confirmation of LS diagnosis, so that relatives can be consequently offered predictive testing. Variants assigned to class 1 and 2 correspond to definitely and likely neutral/not pathogenic (or of low clinical impact) sequence changes, respectively; their detection is not followed by further clinical testing in the family. Finally, class 3 includes all those variants whose clinical and/or functional effects cannot be determined, due to either insufficient (e.g., detection in a single family) or contradictory evidence (i.e., discordant results from similar in vitro assays performed in different laboratories); these are also called variants of uncertain (or unknown) significance (VUS).
Results
Population Frequency
We first verified variant allele frequencies in control populations (Table 1) . Previous classifications performed by InSiGHT relied on frequencies reported in the 1000 Genomes Project database (http://www.1000genomes.org/), in addition to data published or reported by single centers on local populations. In this study, we used values from the Exome Aggregation Consortium (ExAC), which is a more comprehensive dataset and which also incorporates the 1000 Genomes data. We also tested 160 Italian control subjects for 20 variants.
Four variants (MLH1 c.1558+14G>A; MSH2 c.380A>G, c.1511-9A>T, and c.2006-6T>C) that reached minor allele frequencies ࣙ0.01 had previously been classified as Class 1 not pathogenic based on population frequency data alone [Thompson et al., 2014] , and were subjected to further analyses to verify consistency across different points of evidence. The frequency of MSH2 c.380A>G in phase 1 of the 1000 Genomes Project, which had been originally used for classification, was 0.02, whereas the currently reported frequency in ExAC is slightly lower, 0.00692. Of note, the frequencies of MLH1 c.1039-8T>A were 0.00155 in ExAC and 0.02187 in 160 Italian controls, respectively. This difference is likely accounted for by a low quality of calling in the ExAC population, as suggested by the following observations: (1) it is called in less than 80% of individuals in ExAC; (2) the variant was found to be in linkage disequilibrium with MLH1 c.1558+14G>A in the Italian population; and (3) MLH1 c.1558+14G>A had similar polymorphic frequencies in ExAC and in Italian controls (0.03948 vs. 0.02187).
Tumor Pathology Data
Analyses performed on tumors included MSI, MMR IHC, BRAF p.Val600Glu somatic mutation, MLH1 promoter methylation, and LOH (Table 1) .
MSI and/or IHC data were available for 23/24 and 22/24 variants, respectively (Table 1) . These included 12/13 predicted missense changes, for six of which ࣙ2 tumors were investigated. 
RNA Analyses
The MSH2 variant c.2006G>T, which is currently assigned to Class 5 based on evidence of a major splicing defect, was associated with complete exclusion of exon 13 in the minigene assay (Fig. 1) , but with only partial skipping in the LCL from a carrier ( Fig. 2A and B) . Both alleles at position 2006 were detected in the full-length cDNA product from the LCL (Fig. 2C and D) . Partial exon 13 loss was also detected in blood samples drawn in PAXgene tubes from the patient above and from two additional individuals carrying MSH2 c.2006G>T investigated in another laboratory in France, as well as in a LCL established from one of these French carriers (data not shown).
Three other variants (MLH1 c.301G>A and c.1039-8T>A; MSH2 c.2006-6T>C) were associated with partial exon skipping ( Table 2 ; Fig. 1 ; Supp. Figs. S1 and S2) in patient samples, in the ex vivo minigene assay, or in both. These involved in all cases known alternatively spliced transcripts [Genuardi et al., 1998; Thompson et al., 2015] . Interestingly, for MSH2 c.2006-6T>C, partial exon 13 exclusion was only detected by the minigene assay ( Fig. 1) but not in the patient sample [Tournier et al., 2008] , further suggesting that the minigene assay may overestimate the splicing defect for this exon. On the other hand, in this study, partial skipping of exon 12 was observed in lymphoblastoid cells (data not shown) but not with the minigene assay for MLH1 c.1039-8T>A (Supp. Fig. S2 ). The latter result is in accordance with previous findings obtained for this variant by minigene assay [Petersen et al., 2013] .
In addition, the minigene assay showed that Class 5 pathogenic MLH1 c.301G>A p.(Gly101Ser) is associated with loss of the use of an alternative splice site (Supp . Fig. S3) ; while the clinical significance of this finding cannot be established based on the minigene result only, the variant allele should produce only the canonical transcript.
None of the 10 variants tested by the SNuPE assay showed evidence of allelic expression imbalance, consistent with the splicing assay results (Table 2) .
MMR Activity and Protein Expression Analyses
An in vitro MMR complementation assay based on the synthesis of MMR protein in Sf9 insect cells was performed in MMR-defective human cell lines for nine coding variants ( 
No effect
Stable [Takahashi et al., 2007] Proficient [Takahashi et al., 2007; Drost et al., 2010] [Jakubowska et al., 2001; Betz et al., 2010] No allelic imbalance
No effect [Tournier et al., 2008] Discordant results [Raevaara et al., 2005; Takahashi et al., 2007; Xie et al., 2010; Hardt et al., 2011; Hinrichsen et al., 2013] Proficient [Raevaara et al., 2005; Takahashi et al., 2007; Hinrichsen et al., 2013] [Takahashi et al., 2007; Christensen et al., 2009] Proficient [Takahashi et al., 2007; Christensen et al., 2009] p.Phe694Ser and p.Pro696Leu) were found to be unstable in vitro (Fig. 3) 
Clinical Data, Multifactorial Analysis, and Variant Classification
Family history types, co-occurrence of other MMR gene variants, and the components and results of multifactorial analysis are shown in Supp. Tables S1 and S2.
Multifactorial analysis was performed for 14 variants. Using quantitative analysis (based on multifactorial posterior probability) and/or assessment of qualitative criteria, variants were classified according to the five-tier system proposed by InSiGHT (Table 3 ) [Thompson et al., 2014] . The previous InSiGHT assignment of MSH2 c.2006G>T to Class 5 pathogenic based on RNA splicing data was confirmed by the results of multifactorial analysis in this study (Table 3) .
The classification made by InSiGHT was changed for three variants after the addition of novel segregation and molecular tumor data. MLH1 c.301G>A p.(Gly101Ser), originally in Class 4 likely pathogenic, was upgraded to Class 5 pathogenic, whereas variants MSH2 c.1387-8G>T and c.1737A>G p.(Lys579=) were moved from Class 2 likely not pathogenic to Class 1 not pathogenic.
Previous classifications of the other 15 variants were supported by the data obtained. Results of novel RNA analyses performed in this study were in agreement with the assignment to Class 1 not pathogenic of intronic MLH1 variants c.1039-8T>A and c.1558+14G>A. Insufficient evidence to attain a clinically actionable category was available for MLH1 c.1421G>C p.(Arg474Pro), even though novel data from tumor studies brought down the posterior probability of pathogenicity from 0.51 to 0.094.
Discussion
The ultimate purpose of genetic testing for LS and other cancer predisposition syndromes is to reduce cancer morbidity and mortality through the implementation of specific preventive options for carriers of disease-causing variants. Interpreting the significance of DNA variants identified in the diagnostic laboratory is an integral component of clinical DNA testing. The interpretation process is complex, as several independent datasets must be taken into account. Recently, recommendations for clinical classification of MMR gene variants have been formulated [Thompson et al., 2014] . We have performed a thorough investigation of 24 MMR gene sequence variants identified in a single center in order to assess their clinical relevance, using points of evidence that are included in the InSiGHT recommendations, as well as additional potential classification components. Our findings confirm the overall validity of the InSiGHT criteria and suggest that the interpretation process could be improved by introducing some adjustments.
Overall, our results provide support to or improve previous classifications for the 18 variants that had already been assessed by InSiGHT (http://insight-group.org/variants/classifications). For three of these variants (MLH1 c.301G>A; MSH2 c.1387-8G>T and c.1737A>G), a more stable classification, either from Class 4 likely pathogenic to Class 5 pathogenic or from Class 2 likely not pathogenic to Class 1 not pathogenic, was achieved using novel clinical and molecular data. These changes do not affect cancer prevention strategies, since the same clinical recommendations apply to Class 5 and 4 and Class 2 and 1, respectively [Plon et al., 2008] . However, assignments to Class 5 and 1 can be considered definitive, since the likelihood that a variant in either of these categories will be moved to a class associated with different clinical advice is very low [Plon et al., 2008] . The IARC/InSiGHT interpretation criteria advise to consider research testing of further samples/relatives to try and obtain definitive classifications for Class 4 likely pathogenic and Class 2 likely not pathogenic variants [Plon et al., 2008; Thompson et al., 2014] , and our results demonstrate the practical importance of this recommendation. For all three variants, the classification was based on multifactorial analysis, and in all cases the class switch was made possible by the incorporation of few novel data on tumor characteristics and/or segregation, highlighting the relevance of collecting these types of information.
The novel variants MLH1 c.1814A>C p.(Glu605Ala) and MSH2 c.244A>G p.(Lys82Glu) were in Class 4 likely pathogenic and Class 2 likely not pathogenic, respectively, following multifactorial analysis. For both variants, only one clinical observation, that is, molecular information obtained on a single tumor sample (Table  1; Supp. Table S2 ), is available. The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) in the BRCA1/BRCA2 (MIM# 113705 and MIM# 600185) genes recommends that variants attaining thresholds for assignment to clinically actionable classes by multifactorial analysis with limited contribution from clinical or laboratory evidence be considered of uncertain significance until further evidence is accrued (http://enigma.consortium.org/documents/ENIGMA_Rules_2015 _03_26.pdf). We propose to adopt this recommendation also for the MMR genes, especially when there is apparent discordance between functional and clinical evidence, such as for MLH1 p.(Glu605Ala). In particular, for MLH1 variants, additional evidence from BRAF and/or promoter methylation tumor testing could be used to reinforce the evidence in favor of pathogenicity.
The partially discordant RNA splicing results between the minigene assay and analyses of patient-derived samples obtained in this study for MSH2 c.2006G>T suggest that the splicing alteration may not be the only or the major inactivation mechanism for MSH2 c.2006T. Indeed, the functional in vitro assay showed reduced repair activity of the protein encoded by the variant allele, p.Val669 and the variant could be assigned to Class 5 also based on multifactorial analysis. However, complete absence of c.2006T allele in full-length transcript in patient RNA, together with total exon 13 exclusion in a minigene assay, was observed in another study [van der Klift et al., 2015] . Therefore, further studies will be needed to clarify Gly101Ser, MLH1 p.Leu260Arg, MSH2 p.Gly669Val, MSH2 p.Phe694Ser, and MSH2 p.Pro696Leu . R% corresponds to the assay results shown in the figure; X3R% denotes the average of three independent experiments with standard deviations (±). NE-free MOCK and uncomplemented MMR-deficient HCT116 NE and LoVo NE serve as negative controls and HCT116 and LoVo NE complemented by MutLα and Mutsα, respectively, serve as positive controls. The top fragment (3,193 bp) shows the migration of unrepaired linearized GT mismatch-containing construct and the two smaller fragments (1,833 and 1,360 bp) represent the repaired and double-digested fragments. E: The relative repair percentage was calculated in respect to the WT control (MutLα or MutSα, respectively) set as 100 (100,X3R%) according to Drost et al. (2010) and Kantelinen et al. (2012) .
the mechanisms underlying pathogenicity of MSH2 c.2006G>T. At the same time, the interpretation criteria for RNA analyses should be reconsidered based on these apparently inconsistent results.
Minor effects on splicing were observed either on patient RNA or by the minigene assay in this study for the Class 1 not pathogenic variants MLH1 c.1039-8T>A and MSH2 c.380A>G and c.2006-6T>C. All are in Class 1 based on population frequency only, confirming that they have no major clinical effects [Genuardi et al., 1998; Thompson et al., 2015] .
None of the other variants were found to be associated with significant splicing anomalies. Lack of abnormal splicing products was important to assign MLH1 c.307-19A>G, c.1732-19T>C and One of the combinations required for assignment of a variant to Class 1 not pathogenic includes all of the following points of evidence: allelic frequency 0.01%-1%, lack of cosegregation with disease, estimated risk <1.5 determined by case-control studies, and the presence of molecular features not compatible with the involvement of the gene carrying the variant in ࣙ3 tumors; this criterion applies to all types of variants, regardless of their nature and prior probability of altering gene function. Since intronic and synonymous variants have a low a priori likelihood of affecting gene processing, combinations of any of the above evidences (i.e., lack of segregation, population frequency, low estimated risk, and molecular characteristics) and normal splicing patterns could reasonably be considered sufficient for assignment to Class 1. Interestingly, the association of intronic location or synonymous coding nucleotide substitution and the absence of mRNA aberrations demonstrated by in vitro assays has been proposed by the ENIGMA consortium as a criterion for assignment of variants in the BRCA1/BRCA2 genes to Class 1 not pathogenic (http://enigmaconsortium.org/documents/ENIGMA_Rules_2015-03-26.pdf). Data from our study indicate that it would be justified to consider homogenization of the Class 1 criteria for intronic/synonymous substitutions between the ENIGMA and InSiGHT consortia. Nine missense variants were investigated by in vitro MMR assay based on the production of MSH2 or MLH1 proteins in Sf9 insect cells and subsequent complementation of human MMR-deficient cell lines. The same assay had been previously used for three other missense substitutions found in our series [Raevaara et (Arg687Trp) are assigned to Class 5 pathogenic despite the results of the functional assays, which show inconclusive data on protein expression and normal MMR activity, with discordant observations across different studies. However, both are associated with an abundance of clinical data, allowing them to overcome the Class 5 pathogenic posterior probability threshold using multifactorial analysis. At the same time, discordant tumor pathology findings, including samples that were MSS and/or expressed MLH1, have also been reported for both variants. It will be interesting to verify the degree of phenotypic expression associated with these two variants. By analogy with equivocal functional results obtained on the BRCA1 variant p.Arg1699Gln [Spurdle et al., 2012] , they might be considered as candidate intermediate risk variants. Notably, other MLH1 missense substitutions located in proximity of these variants are associated with proficient repair but reduced or inconclusive protein expression data; these include, for instance, While LOH is an important silencing mechanism of the wild-type allele [Alemayehu et al., 2007] , so far it has not been considered as a point of evidence for MMR gene variant classification by InSiGHT. This is due to several reasons, including multiple observations of loss of variant pathogenic alleles in cancers from MMR gene carriers and technical difficulties, that is, due to the potential presence of MSI hampering analysis of LOH using microsatellite markers . The findings from this study, especially the observation of loss of the variant allele in samples from carriers of Class 1 not pathogenic and Class 2 likely not pathogenic variants, confirm that LOH should be considered with caution for the interpretation of variant pathogenicity in the MMR genes. Studies on large series are needed to assess the usefulness of this marker and its predictive value.
The evaluation of multiple clinical parameters and functional assays undertaken in this study allows refining the strategy for the clinical classification of MMR gene variants. Intronic and synonymous variants that cannot be tested in the in vitro MMR assay should be assessed for effects on RNA processing, by detection of aberrant transcripts (in the presence of NMD inhibitors) and ASE (in the absence of NMD inhibitors). We suggest that when no major alteration is observed, the variant could be assigned to Class 1 not pathogenic, even without further evidence (from e.g., segregation and tumor characteristics), as stated by ENIGMA for BRCA1 and BRCA2. The underlying rationale is that the probability that an intronic variant with no documented splicing aberration will cause high tumor risk is very low, <1/1,000.
For potential missense variants, concordant evidence in favor or against pathogenicity should be derived both from functional assays-RNA first, and if normal, protein-and clinical data. Given the importance of obtaining segregation and molecular tumor results for the purpose of variant classification, any attempt should be made to test additional patients and samples, especially from carriers of missense variants that are usually more difficult to classify as compared with silent and intronic changes.
Finally, classifications obtained by multifactorial analysis should be supported by multiple data points; this could be achieved by requiring a minimum threshold or different points of evidence from clinical and tumor data to allow assignment to a clinically actionable class.
